Do you want to read an article? Please log in or register.
Major Adverse Cardiovascular Events in Men with High-risk Localized or Metastatic Prostate Cancer Starting Long-term Hormone Therapy in the STAMPEDE Trial
Genitourinary Cancer
Indications
Related content
Genitourinary Cancer
ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer
J Clin Oncol
Williams S, Sweeney CJ, Thomas H, Mak B, Zhang A, Lim TS, Jose C, Martin J, Patanjali N, Pryor D, Tran P, Mangar S, Mihai AM, Thomas C, Gampenrieder S, Yip S, Cheung L, Lee S, Goodwin A, Haworth A, Walsh A, Kelly PJ, Hughes S, Martin A, McDermott R, Stockler M, Davis ID, Nguyen PL
doi: 10.1200/JCO-26-01794
Genitourinary Cancer
Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer
Ann Oncol
Parker CTA, Huang HC, Grist E, Mendes L, Yamashita R, Croucher D, Sachdeva A, Murphy L, Liu VYT, Vidal SS, Todorovic T, Lall S, Goncalves M, Thakali S, Wingate A, Zakka L, Wetterskog D, Nowakowska K, Amos CL, STAMPEDE Collaborators, Berney DM, Tran PT, Spratt DE, Sydes MR, Brown LC, Zhao SG, Nguyen P, Clarke NW, Sweeney CJ, Stewart EL, Parmar MKB, Esteva A, James ND, Attard G
doi: 10.1016/j.annonc.2026.05.708
Genitourinary Cancer
Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial
Eur Urol
Saad F, Shore N, Vjaters E, Olmos D, Littleton N, Testa I, Mo M, Verholen F, Srinivasan S, Haresh KP
doi: 10.1016/j.eururo.2026.07.026
Genitourinary Cancer
Impact of Intraprostatic Simultaneous Integrated Boost on Long-Term Outcomes in Unfavorable Intermediate-Risk Prostate Cancer Treated With Dose-Escalated Radiotherapy and Short-Term Androgen Deprivation Therapy
Prostate
Onal C, Elmali A, Demirhan B, Senturk E, Erpolat P, Guler OC
doi: 10.1002/pros.70167
CHICAGO 2026
Genitourinary Cancer
LBA1: PROTEUS: The final analysis supports perioperative apalutamide plus ADT in patients with high-risk localized or locally advanced prostate cancer
Genitourinary Cancer
Treatment Effect of Perioperative (Neoadjuvant and Adjuvant) Apalutamide plus Androgen-deprivation Therapy Versus Radical Prostatectomy Alone in Patients with High-risk Localized or Locally Advanced Prostate Cancer from the PROTEUS Substudy
Eur Urol
Briganti A, Steuber T, Shore ND, Gleave M, Kretschmer A, Wetherhold L, Efstathiou E, Cahn DJ, Damião R, De La Taille A, Byun SS, Hadaschik BA, Imbroda BH, Soto ÁJ, Merseburger AS, Simone G, Rooney B, Mikerin D, Li Z, Miladinovic B, McCarthy SA, Wildgust M, Mundle SD, Kibel AS, Taplin ME
doi: 10.1016/j.eururo.2026.10.016
Genitourinary Cancer
Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Eur Urol
Nguyen DD, Tadayon Najafabadi B, Lin L, Kwong JCC, Miller E, Zlotta AR, Fleshner NE, Hird AE, Lofters AK, Wallis CJD, Rosella LC, Dahm P, Guyatt G, Kulkarni GS
doi: 10.1016/j.eururo.2026.04.005
Genitourinary Cancer
Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference
Eur Urol
Gillessen S, Turco F, Davis ID, Efstathiou JA, Emmett L, Fizazi K, James ND, Shore N, Small EJ, Smith M, Sweeney CJ, Tombal BF, Walz J, Zilli T, Lin HM, Pedrani M, Puglisi M, Achard V, Agarwal N, Aggarwal R, Antonarakis ES, Aparicio A, Armstrong AJ, Bastos DA, Attard G, Axcrona K, Ayadi M, Batra A, Beltran H, Bjartell A, Blanchard P, Bossaert F, Bourlon MT, Briers E, Briganti A, Buttigliero C, Castellano D, Castro E, Cheng HH, Chi KN, Chiong E, Clarke N, Cornford P, Dai B, Santis M, Deschamps A, Duran I, Ekeke ON, El Nahas TIH, Fanti S, Fatiregun OA, Fay A, Fong PC, Fonteyne V, Fossati N, Francolini G, Freedland S, Quiroga MNG, George DJ, Giannarini G, Gleave ME, Gravis G, Greene K, Hadaschik B, Hakim L, Halabi S, Heidegger I, Heinrich D, Herrmann K, Hofman MS, Hong SK, Hope TA, Horvath LG, Hussain MHA, Jereczek-Fossa BA, Jones B, Jones RJ, Joshua AM, Kanesvaran R, Keizman D, Khauli RB, Kristiansen G, Lang J, Loblaw A, Loeb S, Mahal BA, Maluf FC, Mateo J, Matheson D, Matikainen MP, McDermott R, McKay RR, Mehra N, Merseburger AS, Michalski J, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Mutambirwa SBA, Nguyen PL, O'Sullivan JM, Oh WK, Oprea-Lager D, Ost P, Padhani AR, Paller CJ, Pang JS, Papatsoris A, Parker C, Patašius A, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Ryan CJ, Rylance A, Saad F, Sade JP, Samuels A, Sandhu S, Sartor OA, Schaeffer EM, Schmidt-Hegemann NS, Seibert TM, Sharifi N, Skoneczna IA, Sokolova A, Spratt DE, Srinivas S, Suzuki H, Taplin ME, Karlsson CT, Tilki D, Uemura H, Ürün Y, van As N, van den Bergh R, Vapiwala N, von Amsberg G, Wei Q, Yamoah K, Ye D, Yu EY, Zapatero A, Omlin A
doi: 10.1016/j.eururo.2026.09.027
Genitourinary Cancer
Effect of [(68)Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial
Lancet Oncol
Buteau JP, Moon D, Fahey MT, Roberts MJ, Ayati N, Papa N, Murphy DG, Kasivisvanathan V, Dhillon HM, Du YT, Dundee P, Foudoulis J, Hennes D, Hutton AC, Idiare J, Jack G, Kamath S, Lee SN, Lee SF, Lee ST, Leslie S, Levy SM, Link E, Mitchell C, Morigi JJ, Nguyen A, Olphert J, Patel MI, Pattison DA, Pearce A, Perera M, Thanigasalam R, Thomson A, Yaxley J, Thompson J, Hofman MS, Emmett L, PRIMARY2 Trial Investigators
doi: 10.1016/S1470-2045(26)00120-8